SA Hurvitz

Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

Shanu Modi, Lajos Pusztai, Andres Forero et al. · Cancer Research · 2018 · 67 citations

Breast Oncology, Immunology, Pathology +19

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

Fabrice André, Mario Campone, SA Hurvitz et al. · Journal of Clinical Oncology · 2008 · 52 citations

Breast Oncology, Akt/mtor Activation, Weekly Paclitaxel +18

A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.

Fabrice André, Thomas Bachelot, Mario Campone et al. · Journal of Clinical Oncology · 2011 · 32 citations

Tumor Biology, Breast Oncology, Oncology +15

Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

DJ Slamon, SA Hurvitz, Steven Applebaum et al. · Journal of Clinical Oncology · 2010 · 30 citations

Breast Oncology, Medicine, Pharmacology +15

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Debu Tripathy, Joohyuk Sohn, S-A. Im et al. · Cancer Research · 2018 · 30 citations

Breast Oncology, Gynecology, Pharmacotherapy +19